Trimeris, Inc.
32Patents
2Active
32Granted
37Portfolio score
Filing activity: Jun 7, 1994 → Oct 20, 2008 · 2 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6017536A | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities | Chemistry; Metallurgy | 46 | Expired |
| US6015881A | Methods and compositions for peptide synthesis | Chemistry; Metallurgy | 41 | Expired |
| US6060065A | Compositions for inhibition of membrane fusion-associated events, including influenza virus transmission | Emerging Cross-Sectional Technologies | 36 | Expired |
| US6281331A | Methods and compositions for peptide synthesis | Chemistry; Metallurgy | 33 | Expired |
| US6013263A | Measles virus peptides with antifusogenic and antiviral activities | Emerging Cross-Sectional Technologies | 31 | Expired |
| US6258782A | Hybrid polypeptides with enhanced pharmacokinetic properties | Chemistry; Metallurgy | 30 | Expired |
| US6469136B1 | Methods and composition for peptide synthesis | Emerging Cross-Sectional Technologies | 28 | Expired |
| US6068973A | Methods for inhibition of membrane fusion-associated events, including influenza virus | Emerging Cross-Sectional Technologies | 28 | Expired |
| US6228983A | Human respiratory syncytial virus peptides with antifusogenic and antiviral activities | Emerging Cross-Sectional Technologies | 27 | Expired |
| US6475491B1 | Treatment of HIV and other viral infections using combinatorial therapy | Chemistry; Metallurgy | 23 | Expired |
| US6348568B1 | Hybrid polypeptides with enhanced pharmacokinetic properties | Chemistry; Metallurgy | 22 | Expired |
| US6656906B1 | Hybrid polypeptides with enhanced pharmacokinetic properties | Emerging Cross-Sectional Technologies | 19 | Expired |
| US6518013B1 | Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission | Chemistry; Metallurgy | 19 | Expired |
| US6541020B1 | Methods and compositions for administration of therapeutic reagents | Chemistry; Metallurgy | 17 | Expired |
| US6054265A | Screening assays for compounds that inhibit membrane fusion-associated events | Emerging Cross-Sectional Technologies | 16 | Expired |
| US6479055B1 | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission | Emerging Cross-Sectional Technologies | 16 | Expired |
| US6093794A | Isolated peptides derived from the Epstein-Barr virus containing fusion inhibitory domains | Emerging Cross-Sectional Technologies | 15 | Expired |
| US7030150B2 | Benzimidazole compounds and antiviral uses thereof | Chemistry; Metallurgy | 13 | Expired |
| US6562787B1 | Hybrid polypeptides with enhanced pharmacokinetic properties | Chemistry; Metallurgy | 8 | Expired |
| US6861059B2 | Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations | Chemistry; Metallurgy | 8 | Expired |
| US6750008B1 | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission | Physics | 7 | Expired |
| US7456251B2 | HIV fusion inhibitor peptides with improved biological properties | Physics | 5 | Active |
| US6440656B1 | Methods for the inhibition of respiratory syncytial virus transmission | Emerging Cross-Sectional Technologies | 5 | Expired |
| US6623741B1 | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission | Chemistry; Metallurgy | 3 | Expired |
| US7045552B2 | Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy | Human Necessities | 3 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.